State Policy Documents
This page will contain policy documents about state specific legislation or regulation. The page will be updated as more state documents become available.
Insurance Marketplace Scorecard
This scorecard is a tool to help you evaluate qualified health plans in the insurance marketplace, and ensure the plan you select includes the appropriate combination of essential health benefits and benefit designs to guarantee access to the full range of cancer therapies and services. Click here to download.
Oral Chemo Parity Landscape
This map shows all of the states that have either passed Oral Parity legislation or have a bill pending in 2013. Click here to download.
The Leukemia, Lymphoma and Myeloma Research, Education and Treatment Program (S.1976/A.558) would promote and fund research, education and treatment programs designed to assist those diagnosed with blood cancer in New York State. Additionally, this legislation would place a "check-off box" on both individual and corporate income tax returns to allow New Yorkers to contribute to the support of this important program.
An LLS advocate, Ms. Dorothy Spriggs, testified before the Maryland Senate Finance committee in support of legislation that would limit the duration of a step therapy of fail first protocol imposed by a specified insurer, nonprofit health service plan, or health maintenance organization. This means that patients would be able to get the treatment that their doctors want to prescribe covered by their insurance faster, instead of having to go on other treatment regimes first and fail those before getting the doctors preferred treatment.
This letter, and many others, were sent to the California Health Benefit Exchange to comment on the proposed Standard Plan Benefit Design. LLS advocates told the Covered California Board that "metal tiered" plans that have specialty tiers with high co-insurances for cancer medications and only a select number of available drugs per class would hurt California cancer patients.
"On behalf of the Leukemia & Lymphoma Society and the blood cancer patients we serve throughout the state of Massachusetts, we thank you for the opportunity to submit written testimony on Senate Bill 477. Sponsored by Chairman Petruccelli, this important bill would cap patient cost-sharing amounts for ?specialty tier? drug coverage."
"On behalf of the Leukemia & Lymphoma Society and the blood cancer patients we serve throughout the state of Massachusetts, we thank you for the opportunity to comment on Senate Bill 439, which would create guidelines for the use of step therapy in drug formularies. Step therapy, also known as ?fail first,? is a widely-used technique that insurers use to control drug costs. Step therapy requires patients to first try and fail on medications selected by their insurer?based on cost?before a patient is granted coverage for the medication that had been initially prescribed by the patient?s healthcare provider."
"In addition to the ACA-related requirements, emerging technologies, changes in care delivery and payment models require a transparent mechanism to judge whether health plans have robust provider networks to ensure patient access to evidenced-based medical care. Because many of these innovations (e.g. telemedicine, care coordination) can improve access to and the quality of care, it is critical that regulators and other stakeholders examine and update current standards for network adequacy in new models of care, and the growing trend to address beneficiary access issues via non-face-to-face encounters. As states and the federal government assess and update their requirements for network adequacy, focus must be maintained where it belongs ? ensuring patient access."